Publicaciones en las que colabora con Mercedes Iñarrairaegui Bastarrica (75)

2024

  1. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

    Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

  2. The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies

    Annals of Surgery, Vol. 280, Núm. 1, pp. 46-55

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

    Cancers, Vol. 15, Núm. 3

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  3. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

  4. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 12, pp. 2555-2566

  5. Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes

    Langenbeck's Archives of Surgery, Vol. 407, Núm. 3, pp. 1099-1111

2021

  1. 3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 10, pp. 3048-3057

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?

    Hepatology

  4. The joint use of 99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning

    EJNMMI Research, Vol. 11, Núm. 1

2020

  1. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT

    CardioVascular and Interventional Radiology, Vol. 43, Núm. 8, pp. 1165-1172

2019

  1. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

    Hepatology, Vol. 70, Núm. 2, pp. 547-562

  2. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

    Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884

2018

  1. Immunotherapy of hepatocellular carcinoma: Facts and hopes

    Clinical Cancer Research, Vol. 24, Núm. 7, pp. 1518-1524

  2. Pneumatocele during sorafenib therapy: First report of an unusual complication

    Oncotarget, Vol. 9, Núm. 5, pp. 6652-6656

  3. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 10, pp. 1721-1730

  4. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis of randomized trials

    OncoTargets and Therapy, Vol. 11, pp. 7315-7321